Intracranial angioleiomyoma: a case series of seven patients and review of the literature
Journal of Neuro-Oncology · 2024
DOI: 10.1007/s11060-024-04734-y ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Neuro-Oncology, 2024. Verfasst von Meltem Ivren und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Heidelberg University, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany. meltem.ivren@med.uni-heidelberg.de. Hauptthemen laut MEDLINE: Angiomyoma, Brain Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medizinische Fakultät Heidelberg der Universität Heidelberg.
Abstract (Originalsprache)
Purpose
Angioleiomyoma, predominantly arising from the extremities, is a benign soft tissue tumor. Reports on its intracranial location are rare. We assessed clinical, radiological, and pathological features of intracranial angioleiomyoma (iALM) treated at our neurosurgical institution.
Methods
We consecutively enrolled all patients with neuropathologically confirmed iALM treated at a single neurosurgical institution between 2013 and 2021. Clinical and imaging data were collected, and histological tissue sections were analyzed. A review of the literature on iALM was conducted.
Results
Seven patients with iALM (four female) with a median age of 45 years (range: 32–76 years) were identified. In three cases, the lesion was found incidentally. In magnetic resonance imaging (MRI), all tumors were hypo- to isointense on T1-weighted, hyperintense on T2-weighted sequences, and gadolinium-enhancing. A strong FLAIR signal was seen in six patients. Surgery consisted of gross total resection in all cases without perioperative complications. Neuropathological staining was positive for smooth muscle actin (SMA) in all lesions. Mature smooth muscle cells arranged around blood vessels were typically observed. The Ki-67 index was ≤ 3%. The patients were discharged after a median of 6 days (range: 4–9 days). During a median follow-up time of 14 months (range: 4–41 months), no tumor recurrence occurred. In the current literature, 42 additional cases of iALM were identified.
Conclusion
Intracranial angioleiomyoma is a benign soft tissue tumor treated by gross total resection. Tumor morphology and positive staining for SMA lead to the neuropathological diagnosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurosurgery, Heidelberg University, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany. meltem.ivren@med.uni-heidelberg.de.
- Department of Neuopathology, Heidelberg University, Im Neuenheimer Feld 672, Heidelberg, Germany.
- Department of Neurosurgery, Heidelberg University, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.
- Department of Neuroradiology, Heidelberg University, Im Neuenheimer Feld 400, Heidelberg, Germany.
- Department of Neuroradiology, Klinikum Darmstadt, Grafenstraße 9, Darmstadt, Germany.
- Department of Neurosurgery, Heidelberg University, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany. alexander.younsi@med.uni-heidelberg.de.
Förderung
- Medizinische Fakultät Heidelberg der Universität Heidelberg
Zitieren
APA
Ivren, M., Cherkezov, A., Reuss, D., Haux, D., Herold-Mende, C., Mohr, A., Krieg, S. M., Unterberg, A., & Younsi, A. (2024). Intracranial angioleiomyoma: a case series of seven patients and review of the literature. Journal of Neuro-Oncology. https://doi.org/10.1007/s11060-024-04734-y
Vancouver
Ivren M, Cherkezov A, Reuss D, Haux D, Herold-Mende C, Mohr A, et al. Intracranial angioleiomyoma: a case series of seven patients and review of the literature. Journal of Neuro-Oncology. 2024. doi:10.1007/s11060-024-04734-y
BibTeX
@article{Ivren2024,
author = {Ivren, Meltem and Cherkezov, Asan and Reuss, David and Haux, Daniel and Herold-Mende, Christel and Mohr, Alexander and Krieg, Sandro M and Unterberg, Andreas and Younsi, Alexander},
title = {Intracranial angioleiomyoma: a case series of seven patients and review of the literature},
journal = {Journal of Neuro-Oncology},
year = {2024},
doi = {10.1007/s11060-024-04734-y}
}
EUVIMED